Company Team Search Site Map Careers Privacy Statement
:: Home
:: About Us
:: R&D
:: Products
:: Services
:: Infrastucture
:: Contact us
Virchow Products
Company History

As part of expansion in pharma, Virchow group entered into fast growing Bio-pharma sector. In the year 2000, we began with a Biotech R&D center in Nashville, TN., USA. We identified niche products (mostly bio-generic recombinants and non-recombinant biomolecules), developed cost effective processes, and then relocated the operations to India in 2001.


In India we are currently housed in a 125,000 sqft. facility dedicated for biotech operations. This facility is equipped to manufacture topical biologicals, recombinants to parenteral bio-pharmaceuticals. We have also built a separate animal house to undertake pre-clinical studies and created a clinical team for the conduct human clinical trials.

We pioneered the development of novel and innovative products based on advances in recombinant DNA and molecular biology. We introduced for the first time two bio-generic human therapeutics, Healace (rh PDGF-BB, marketed in India as Plermin by Dr. Reddy's Laboratories) and Osteotide (marketed in India as Bonista by Ranbaxy Laboratories Limited).

These products have improved the lives of hundreds of thousands of patients suffering from conditions related to chronic diabetic ulcers and osteoporosis. We at Virchow Biotech continue to fulfil our mission by expanding our business to serve patients around the world in need of treatment in the areas of Advanced Wound Care; Surgical Hemostasis; Opthalmology; Orthopaedics and Oncology amongst others.

 

News & Events

Virchow Biotech is filing for U.S.Food and Drug administration’s (FDA) approval for its in house developed advanced wound care products.

Virchow Biotech received Drug control’s (DCGI) approval for conducting clinical trials on periogen, an indigenously developed recombinant therapeutic product for periodontal diseases

Virchow Biotech and Ranbaxy signed an MOU to market Virchow’s indigenously developed recombinant therapeutic protein for osteoporosis treatment. We are the first in the world to launch this biogeneric product